Emergency use approval of Pfizer’s Covid-19 pill
The U.S. Food and Drug Administration (FDA) has granted an emergency use permit to the pharmaceutical company Pfizer’s antiviral Covid-19 pill, Paxlovid. The Kovid-19 pill, which was first approved by the FDA, will be used in a total of 30 pieces for 5 days.
In the statement made by the US Food and Drug Administration (FDA), it was announced that the antiviral pill Paxlovid, developed by the US-based pharmaceutical company Pfizer, was approved for the emergency use for the treatment of mild to moderate coronavirus disease. It was stated that the pill can be used by patients aged 12 and over, can only be obtained with a prescription, and should be taken as soon as possible after the diagnosis of Kovid-19 and within 5 days after the onset of symptoms. While emphasizing that Paxlovid will be used together with the antiviral drug called “Ritonavir”, it was stated that a total of 30 pills (2 Nirmatrelvir and 1 Ritonavir) will be taken 2 times a day for 5 days. It was reported that the known and potential benefits of Paxlovid outweigh the risks.
- read more: Contact restriction requested due to omicron variant in Germany
- Canadian Prime Minister Trudeau quarantined himself
Paxlovid became the first antiviral Covid-19 pill allowed for coronavirus patients to use at home before it became too severe to be hospitalized.
“A GREAT STEP FORWARD IN THE FIGHT AGAINST THE EPIDEMIC”
Patrizia Cavazzoni, Director of the FDA Center for Drug Evaluation and Research, said: “Today’s authorization has made a treatment for Covid-19 in pill form possible. This is a big step forward in the fight against the global epidemic.” “This permit provides a new tool to combat Covid-19 at a critical time in the epidemic as new mutations emerge and promises to make antiviral therapy more accessible for patients at high risk of worsening Covid-19 disease,” Cavazzoni said.
GROUNDBREAKING TREATMENT WILL CHANGE THE WAY WE TREAT COVID-19″
Pfizer CEO Albert Bourla said: “The endorsement of Paxlovid represents another example of how science will help us finally beat this epidemic that continues to upend lives around the world, even 2 years later. It has been shown to significantly reduce hospitalizations and deaths, and “This breakthrough treatment available at home will change the way we treat COVID-19 and hopefully help reduce some of the key pressures our healthcare and hospital systems are facing.” “Pfizer is ready to begin immediate delivery in the US to help Paxlovid reach eligible patients as soon as possible,” Bourla said.
APPLICATION MADE TO FDA IN NOVEMBER
Pfizer applied for emergency use approval by submitting the data to the U.S. Food and Drug Administration (FDA) on November 16. The US pharmaceutical company announced that its drug reduced hospitalization and death rates by 89 percent in intermediate and high-risk patients.
